Home
    Disclaimer
    Afloqualone molecular structure

    Afloqualone Stats & Data

    Aroft Hq-495 Arofuto
    NPS DataHub
    MW283.31
    FormulaC16H14FN3O
    CAS56287-74-2
    IUPAC6-Amino-2-(fluoromethyl)-3-(2-methylphenyl)quinazolin-4-one
    SMILESFCc1nc2ccc(N)cc2c(=O)n1c1ccccc1C
    InChIKeyVDOSWXIDETXFET-UHFFFAOYSA-N
    Psychoactive Class Depressant
    Half-Life Unknown in humans as of 2025; no reliable pharmacokinetic half‑life data located in standard references.

    Pharmacology

    DrugBank

    Metabolism

    Afloqualone has known human metabolites that include Afloqualone N-glucuronide.

    Receptor Profile

    Receptor Actions

    Modulators
    GABA-A receptor positive allosteric modulator (non-benzodiazepine site)

    Tolerance & Pharmacokinetics

    drugs.wiki
    Half-Life
    Unknown in humans as of 2025; no reliable pharmacokinetic half‑life data located in standard references.
    Addiction Potential
    Moderate-to-high (class effect for GABAergic sedative–hypnotics). Regular use can produce tolerance, withdrawal, and compulsive redosing risk similar to other GABA_A PAMs.

    Tolerance Decay

    Full tolerance 3d Half tolerance 14d Baseline ~28d

    Time‑course estimates derive from community reports and general GABAergic class effects (anecdotal). Avoid daily use to prevent rapid tolerance and physiologic dependence.

    Cross-Tolerances

    Benzodiazepines
    50% ●○○
    Barbiturates
    50% ●○○
    Methaqualone
    70% ●○○
    Other GABA_A PAMs
    40% ●○○

    Harm Reduction

    drugs.wiki

    • Strong photosensitizer: drugbank classifies afloqualone under photosensitizing and radiation‑sensitizing agents; minimize UVA/UVB exposure during use and for at least 24–48 h after, wear protective clothing, and use broad‑spectrum high‑SPF sunscreen. Severe phototoxic or photoallergic dermatitis can occur; discontinue and seek medical care if rash or blistering appears. • As a CNS depressant and centrally acting muscle relaxant, it can synergize dangerously with other depressants (alcohol, opioids, GHB, benzodiazepines, barbiturates, carisoprodol, and Z‑drugs), markedly increasing risk of respiratory depression, aspiration, and loss of consciousness. • Do not drive, swim, climb, or operate machinery on the day of use; ataxia and delayed psychomotor impairment are common at moderate/high doses and have been associated with falls and accidents in the broader GABAergic class. • Tramadol is specifically risky due to its pro‑convulsant and serotonergic properties; avoid co‑use. • Consider additive photosensitivity if taking other photosensitizing medicines (e.g., tetracyclines, quinolones, thiazide diuretics, retinoids, psoralens); avoid tanning beds and medical phototherapy around dosing. • Human pharmacokinetics are poorly characterized in standard references; half‑life and active metabolites are not well established, so redosing can unpredictably increase sedation the following hours. • Treat suspected overdose with supportive care (airway, breathing, circulation); naloxone will not help (non‑opioid). Flumazenil reverses benzodiazepines at the BZD site and is generally ineffective against non‑benzodiazepine GABA_A modulators; routine use is not recommended due to seizure risk. • As an obscure/RC compound, identity and potency can vary; prefer lab testing where available. If only reagents are available, note that methaqualone‑class reagents are limited and may be non‑specific—interpret cautiously. • Best‑practice dosing includes an allergy test (1–5 mg) and accurate measurement (milligram scale or volumetric dosing) to avoid inadvertent overdosing.

    ← Back to Afloqualone